

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisal (STA)

## Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

## Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• AOP Orphan Pharmaceuticals AG (Ropeginterferon alfa-2b)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• African Caribbean Leukaemia Trust</li> <li>• Anthony Nolan</li> <li>• Bloodwise</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• DKMS</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia CARE</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• MPN Voice</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• Thrombosis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Blood Transfusion Society</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• British Society of Interventional Radiology</li> <li>• Cancer Research UK</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Hospital Information Services – Jehovah's Witnesses</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• AOP Orphan Pharmaceuticals AG (anagrelide)</li> <li>• Aspen (busulfan, melphalan)</li> <li>• Bayer (interferon beta-1b)</li> <li>• Biogen Idec (interferon beta-1a)</li> <li>• Consilient Health (anagrelide)</li> <li>• Dr. Reddy's Laboratories (anagrelide)</li> <li>• Generics UK T/A Mylan (anagrelide)</li> <li>• Glenmark Pharmaceuticals (anagrelide)</li> <li>• Kent Pharmaceuticals (anagrelide)</li> <li>• Medac GmbH (hydroxycarbamide)</li> <li>• Merck Sharp &amp; Dohme (interferon alfa-2b, interferon beta-1a)</li> <li>• Novartis (interferon beta-1b, ruxolitinib)</li> </ul>

Provisional stakeholder list for the proposed technology appraisal of ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596. Issue date: May 2019

<ul style="list-style-type: none"> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Forum on Haemoglobin Disorders</li> <li>• UK National Screening Committee</li> <li>• UK Oncology Nursing Society</li> <li>• United Kingdom Primary Immunodeficiency Networks</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Darlington CCG</li> <li>• NHS England</li> <li>• NHS Wyre Forest CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Roche (interferon alfa-2a)</li> <li>• Sandoz (anagrelide)</li> <li>• Takeda/Shire Pharmaceuticals (anagrelide)</li> <li>• Zentiva (anagrelide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• Leuka</li> <li>• Leukaemia Busters</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>
---	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

## Definitions:

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.